While not specifically about chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL), these results offer some encouraging news regarding cancer care for adults with predominantly African ancestry in terms of their use of genomic testing to help inform their cancer treatments.
Chronic lymphocytic leukemia (CLL) patients treated at academic centers live lived longer than those treated at non-academic centers, but the data was confounded by significant demographic and socioeconomic variation between CLL patients treated at Academic Centers and Non-Academic Centers.
The team at Ohio State University Comprehensive Cancer Center used Surveillance, Epidemiology, and End Results (SEER) data to determine how race and socioeconomic status (SES) affect survival for those with CLL. SEER is a free resource of the NIH, specifically the National Cancer Institute (NCI), and is “an authoritative
The Bottom Line: Black CLL patients die sooner than their white counterparts, even when controlling for other risk factors. In addition, the gap in overall survival has not improved between 2004 to 2018.
hile this abstract presented at ASH 2021 (American Society of Hematology Annual Meeting and Exposition) was not specific to CLL or chronic lymphocytic leukemia, it did show that where you live profoundly influences your survival odds with leukemia.